Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Metastatic NSCLC is “stage IV” or “advanced ... Powerful drugs travel through your bloodstream to kill cancer cells. Targeted therapy. Treatment that homes in on proteins that play ...

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, ...

Servier will be responsible for development and global commercialisation of the therapy for several indications.

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...

Our partnership to develop BDTX-4933 is an important opportunity in targeted cancer therapies ... of BDTX-4933 across multiple indications, including non-small cell lung cancer (NSCLC), with potential ...